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Vaccine RepoRts
Background: Both the 13- and 10-valent pneumococcal conjugate vaccines 
(PCV-13; PCV-10) are immunogenic and effective against vaccine-type 
pneumococcal disease when given to young children. However, limited data 
are available regarding the interchangeability of these 2 vaccines.
Methods: UK children (n = 178) who had previously been vaccinated with 
PCV-13 at 2 and 4 months were randomized to receive either a PCV-13 or 
a PCV-10 booster at 12 months of age. PCV-13 vaccine-type antipolysac-
charide serum immunoglobulin G (IgG) concentrations and opsonophago-
cytic assay titers were measured before and at 1 and 12 months following 
vaccination. The primary objective was to assess noninferiority of PCV-10 
compared with PCV-13.
Results: For 8 of the PCV-10 serotypes at least 97% of participants in both 
groups had IgG concentrations ≥0.35 µg/mL at 1 month after  vaccination; 
inferior responses were seen for serotypes 5 and 9V following the PCV-10 
compared with the PCV-13 booster. Post booster geometric mean IgG con-
centrations and opsonophagocytic assay titers were significantly superior 
for most serotypes in PCV-13 compared with PCV-10 recipients, whereas 
similar or inferior responses were seen for serotypes 4, 18C, and 19F. 
Although some increase in antibody was seen in PCV-10 recipients against 
the serotypes 6A and 19A (serotypes that cross-react with 6B and 19F in 
PCV-10, respectively) at 1-month post booster, these responses were signifi-
cantly lower than in the PCV-13 group.
Conclusions: In PCV-13 primed infants, a PCV-10 booster is generally less 
immunogenic than a PCV-13 booster. For the 3 serotypes in PCV-10 with 
higher antigen content and/or conjugation to diphtheria or tetanus toxoid 
carrier proteins, higher or similar booster responses were seen in PCV-10 
recipients. Although these findings suggest that responses are generally bet-
ter with a PCV-13 booster among PCV-13 primed children, the clinical sig-
nificance of these differences in immunogenicity is unclear.
Key Words: interchangeability, pneumococcal conjugate vaccine, immu-
nogenicity, children
(Pediatr Infect Dis J 2016;35:787–793)
The encapsulated bacterium Streptococcus pneumoniae com-monly causes respiratory infections and may also cause severe 
infections, such as meningitis and sepsis. Pneumococcal protein-
polysaccharide conjugate vaccines (PCVs) were first routinely 
used in childhood immunization programs in children in the USA 
in 2000 and introduced as a 7-valent vaccine (PCV-7) into the 
UK infant immunization schedule in 2006, successfully reducing 
the burden of invasive pneumococcal disease in both countries 
(IPD).1–3 Newer PCVs with extended serotype coverage became 
available in 2009 including either an additional 3 (PCV-10) or 6 
(PCV-13) serotypes. Both vaccines are immunogenic and effective 
against IPD when given to young children in a series of 3–4 vaccine 
doses.3–6 Although both PCV-10 and PCV-13 share 10 serotypes, 
they differ substantially in the concentrations of polysaccharides, 
the method of conjugation, and the type and concentrations of the 
carrier proteins.7
There are several potential advantages of interchanging 
PCVs and using PCV-10 in PCV-13 primed children. The use of a 
novel carrier protein such as nontypeable Haemophilus influenzae-
derived protein D in PCV-10, which is not closely related to an 
antigen included in any concurrently or previously administered 
routine vaccine minimizes the risk of interference related to the 
carrier protein although the effect is usually seen in primary vac-
cination.8 This in turn may enhance immune responses against the 
contained pneumococcal serotypes. In PCV-10, most serotypes are 
conjugated to protein D, which has the potential to induce responses 
that may protect children against nontypeable Haemophilus influ-
enzae disease through an immune response generated by the carrier 
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protein,9,10 however this has yet to be demonstrated. Interchanging 
PCVs may help to improve our understanding of vaccine immuno-
biology, addressing unanswered questions in relation to the interac-
tion of conjugate vaccines with the immune system11 and the poor 
booster responses with certain serotypes.7
This study aimed to investigate the potential of an alterna-
tive booster vaccine to be given to 12-month-old children who have 
been primed with PCV-13 in infancy. immunoglobulin G (IgG) 
concentrations and opsonophagocytic assay (OPA) titers for PCV-
13 serotypes were assessed before, 1 and 12 months following the 
booster. The safety and reactogenicity of the 12-month booster was 
assessed using diary cards containing parental reports of local and 
systemic reactions following vaccination.
MATERIALS AND METHODS
Participants, Recruitment and Design
The study was a randomized controlled clinical trial, which 
was open-labeled for participants and clinical trial staff, but 
blinded for laboratory staff. Ethical approval was obtained from 
the Oxfordshire Research Ethics Committee (reference number 11/
SC/0473) and the study was registered on Clinicaltrials.gov (regis-
tration number NCT01443416). Participants were recruited primar-
ily by information booklets mailed out via the UK National Health 
Application and Infrastructure Services who are responsible for 
the central NHS patient database. Potential study participants were 
healthy 12-month-old children (range 50–58 weeks) at the time of 
enrolment, who were available for the entire study period and had 
received all primary vaccines according to the UK routine immuni-
zation schedule including 2 immunizations of PCV-13 at less than 
6 months of age with a gap of at least 6 weeks between the 2 vacci-
nations. Absolute and temporary exclusion criteria are summarized 
in Table S1, Supplemental Digital Content 1, http://links.lww.com/
INF/C454. Following written informed consent, study participants 
were randomly allocated to receive a booster dose at 12 months of 
either PCV-13 (Prevenar 13/Prevnar 13, Pfizer Inc., New York, NY) 
or PCV-10 (Synflorix, GSK Vaccines, Rixensart, Belgium).
Vaccines and Interventions
Most serotypes contained in PCV-10 are conjugated indi-
vidually to protein D (total dose 9–16 µg), a recombinant form of 
a lipoprotein of nontypeable H. influenzae; serotypes 18C and 19F 
polysaccharides are conjugated to tetanus toxoid (5–10 µg) and 
diphtheria toxoid (3–6 µg), respectively (Table 1). PCV-13 con-
tains saccharides from pneumococcal serotypes 3, 6A and 19A in 
addition to PCV-10 serotypes, individually conjugated to cross-
reacting material (CRM
l97
, total dose of around 34 µg; Table 1). 
Both vaccines (0.5 mL) were administered intramuscularly using 
a 0.6 × 25 mm 23 gauge needle into the anterolateral aspect of 
either thigh. Combined H. influenzae type b/group C meningococ-
cal vaccine and measles, mumps and rubella vaccine were given at 
13 months but did not form part of the study evaluation.
Laboratory Measurements
Serum was separated within 24 hours at the study site and 
stored at −20°C. Antibody measurements were performed at the 
world health organization pneumococcal reference laboratory at 
University College London. Serum concentrations of total anti-
capsular IgG for PCV-13 serotypes were identified by ELISA 
method after absorption with C polysaccharide-containing cell 
wall extract and 22F polysaccharide, and expressed as µg/mL. OPA 
titers against PCV-13 serotypes were measured using a multiplex 
opsonophagocytic assay.12 The lower limit of quantitation for all 
serotypes as established during the validation was 0.150 µg/mL 
for IgG concentrations measured by ELISA and 8 for OPA titers. 
Values below the lower limit of quantitation were replaced with 
0.075 µg/mL and 4, respectively.
Statistical Analysis
Data were log-transformed before analysis and group sum-
maries presented as geometric means with associated 2 sided, 95% 
confidence intervals (CI). In addition, the geometric mean fold-
rise for the serotype-specific antibody measurements was derived 
from the exponent of the within-person difference between the 
log-transformed individual assay result before and after the booster 
dose. The proportion of study participants achieving thresholds of 
0.35 µg/mL for IgG concentrations, or 8 for OPA titers were calcu-
lated within each group and CIs computed using the binomial exact 
method. Similar analyses were performed to calculate proportions 
and 95% CI for rates of local and systemic reactions. Chi-squared 
test (or Fisher exact tests when expected counts were less than 5) 
were used to compare proportions of participants between groups. 
Two-sample t tests or analysis of covariance was used to compare 
the continuous variables with adjustment for baseline values where 
appropriate. Comparisons between the 2 groups were carried out 
based on treatment allocation. Statistical analysis was performed 
using SAS version 9.3 (SAS Institute Inc., USA) and R.13
Study Objectives
The primary objective of this study was to assess whether 
PCV-10 is noninferior to PCV-13 using proportions of partici-
pants with IgG concentrations ≥0.35 µg/mL for PCV-10 serotypes 
1 month following booster vaccination at 12 months of age with 
PCV-10 or PCV-13. Noninferiority of PCV-10 would be shown if 
the CI for the difference between groups (PCV-10 − PCV-13) did 
not include values less than −10% (noninferiority margin). The 
sample size of 84 participants in each of the vaccine groups was 
calculated to allow assessment of noninferiority with a margin of 
10% using 80% power and 2.5% significance level allowing for 
a 15% drop-out rate. During the course of the study, blood sam-
ples for less than 85% of participants were available at 13 months 
of age, therefore more study participants were recruited following 
amendment of the protocol. The intention to treat (ITT) population 
TABLE 1. Pneumococcal Polysaccharide 
Concentrations and Serotype-specific Carrier Proteins 
Contained in PCV-10 and PCV-13
PCV-10* PCV-13†
Serotype
Dose of  
Polysaccharide 
(μg)
Carrier  
Protein
Dose of  
Polysaccharide 
(μg)
Carrier  
Protein
1 1 Protein D 2.2 CRM197
4 3 Protein D 2.2 CRM197
5 1 Protein D 2.2 CRM197
6B 1 Protein D 4.4 CRM197
7F 1 Protein D 2.2 CRM197
9V 1 Protein D 2.2 CRM197
14 1 Protein D 2.2 CRM197
18C 3 Tetanus 
toxoid
2.2 CRM197
19F 3 Diphtheria 
toxoid
2.2 CRM197
23F 1 Protein D 2.2 CRM197
3 2.2 CRM197
6A 2.2 CRM197
19A 2.2 CRM197
*Contains 0.5 mg aluminium phosphate.
†Contains 5 mM succinate buffer and 0.125 mg aluminum phosphate.
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for immunogenicity consisted of all participants receiving a dose of 
PCV-10 or PCV-13 and providing a blood sample at age 13 months. 
Participants with predefined deviations from protocol were removed 
from the per-protocol (PP) population. The PP population was used 
for primary noninferiority analysis, with a sensitivity analysis per-
formed on the ITT population. All other analyses were conducted 
on an ITT population; secondary objectives reported here included 
the immunogenicity and reactogenicity of the booster. Other sec-
ondary objectives that will be reported separately were the assess-
ment of immediate pain at time of injection of the PCV booster 
and the investigation of antigen-specific peripheral blood memory 
B cells in response to vaccination.
RESULTS
A total of 178 children aged 11–13 months, from the 
Oxfordshire region, were recruited and randomized in a 1:1 ratio 
into 2 groups to receive 1 dose of either PCV-10 or PCV-13 at 
12 months of age. Figure 1 shows the number of participants and 
their flow through the study. Baseline demographics of randomized 
participants are shown in Table 2.
One child was enrolled at age 11 months and 5 days, below 
the minimum age for inclusion, and was therefore excluded from 
the PP population (Fig. 1), but included in the ITT population. 
There were a number of protocol deviations related to the timing of 
visits, none of which were thought to significantly affect any of the 
outcome measures. Hence, none of these study participants were 
excluded from the PP population. There were 5 serious adverse 
events (febrile illness, suspected meningococcal sepsis, viral gas-
troenteritis, viral wheeze and febrile convulsion) reported during 
the study none of which were considered related to study vaccines 
and all participants recovered.
At baseline, there were significantly higher IgG GMC seen 
in the PCV-10 compared with the PCV-13 group for serotypes 19F 
and 19A (Fig. 2). For serotype-specific geometric mean OPA titers 
(GMT), group differences were found only for serotype 3 with a 
significantly higher OPA GMT in PCV-10 compared with PCV-13 
recipients (Fig. 3).
Noninferiority Assessment of PCV-10 as an 
Alternative 12-month Booster (PP Population)
Table 3 shows the results of the primary endpoint analysis. 
IgG responses to serotypes 5 and 9V in the PCV-10 group were 
inferior to the PCV-13 group at 13 months when proportions of par-
ticipants with serotype-specific IgG concentrations ≥0.35 µg/mL 
were compared between groups.
Short-term Antibody Response to a Booster 
Dose of PCV-10 Compared With PCV-13 (ITT 
Population)
One month following the booster vaccine, at least 97% of 
participants in each group had IgG concentrations ≥0.35 µg/mL 
for the serotypes they were vaccinated against with the exception 
of serotypes 5 and 9V in the PCV-10 group. For these 2 serotypes, 
which are common to both PCV-10 and PCV-13, the proportions of 
participants with serotype-specific IgG above the threshold were 
significantly higher in PCV-13 compared with PCV-10 recipients 
(Figure S1 and Table S2, Supplemental Digital Content 1, http://
links.lww.com/INF/C454). In addition, these proportions were 
also higher in the PCV-13 group for 2 out of the 3 serotypes only 
included in PCV-13, namely serotypes 3 and 6A but not serotype 
19A (Figure S1 and Table S2, Supplemental Digital Content 1, 
http://links.lww.com/INF/C454).
Post booster IgG GMC were significantly higher in the 
PCV-13 compared with the PCV-10 group for the majority of 
serotypes common to both vaccines (1, 5, 6B, 7F, 9V, 14 and 23F) 
as well as for the serotypes only included in PCV-13 (3, 6A and 
19A) whereas GMCs were significantly higher in PCV-10 com-
pared with PCV-13 recipients only for serotypes 4, 18C and 19F 
(Fig. 2; Table S4, Supplemental Digital Content 1, http://links.
lww.com/INF/C454).
FIGURE 1. CONSORT diagram showing the flow through 
the study. One study participant receiving PCV-10 was 
excluded from the analysis of the primary objective because 
of major protocol violation resulting in n = 69 in the PCV-10 
group at the 13-month visit.
TABLE 2. Baseline Demographics by Group
PCV-10 (n = 87) PCV-13 (n = 90)
N (%) N (%)
Age (mos)
Mean (SD) [min–max] 12.6 (0.4)  
[11.1–13.3]
12.7 (0.4)  
[11.7–13.5]
Sex
  Male 46 (52.9) 58 (64.4)
  Female 41 (47.1) 32 (35.6)
Ethnicity
  White Caucasian/
European
78 (89.7) 74 (82.2)
  Other 9 (10.3) 15 (16.7)
  Unknown 0 (0) 1 (1.1)
SD indicates standard deviation.
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An analysis of covariance model that adjusted for base-
line values, age, sex and ethnicity was used to investigate 
changes from baseline in IgG concentrations between groups. 
Significant increases in IgG concentrations were observed in 
both groups for all serotypes between 12 and 13 months of age 
and group differences from adjusted and unadjusted analyses 
were similar to differences observed in analysis of 13-month 
values alone (Table S6, Supplemental Digital Content 1, http://
links.lww.com/INF/C454).
Serotype-specific functional antibodies were assessed by 
OPA for all PCV-13 serotypes. One month following the booster, at 
least 98% of participants had titers ≥8 and there were no observable 
group differences for all PCV-10 serotypes except for serotypes 1, 5 
and 9V; for these serotypes the proportion of participants with OPA 
titers ≥8 was higher in the PCV-13 than the PCV-10 group. These 
proportions were also higher for all 3 serotypes (3, 6A and 19A) 
only contained in PCV-13 (Table S7 and Figure S2, Supplemental 
Digital Content 1, http://links.lww.com/INF/C454).
Significantly higher post booster GMT were seen in the 
PCV-13 than the PCV-10 group for most serotypes common to both 
vaccines as well as for all 3 serotypes only included in PCV-13. For 
serotypes 4 and 18C, there were no significant differences between 
the groups and for serotype 19F, the OPA response was significantly 
higher in the PCV-10 than the PCV-13 group (Fig. 3; Table S9, Sup-
plemental Digital Content 1, http://links.lww.com/INF/C454).
For both study groups, significant increases in OPA titers for 
all serotypes with the exception of serotype 3 in the PCV-10 group 
were seen between 12 and 13 months of age (Table S11, Supple-
mental Digital Content 1, http://links.lww.com/INF/C454). Analy-
ses of change from baseline to 13 months in OPA titers with adjust-
ment for baseline values, age, sex and ethnicity gave similar results 
to unadjusted analyses of 13 month values although group differ-
ences in immunogenicity for serotypes 1 and 19F were no longer 
observed (Table S11, Supplemental Digital Content 1, http://links.
lww.com/INF/C454).
One-year Antibody Persistence Following a 
Booster Dose of PCV-10 Compared With PCV-13 
(ITT Population)
Group differences in proportions above the IgG or OPA 
thresholds were observed for a number of serotypes at 24 months 
of age, that is, 12 months following the booster. These proportions 
were similarly greater for both measurements for PCV-13 compared 
with PCV-10 recipients for serotypes 6B, 7F and 6A and lower for 
serotype 19F (Figures S1 and S2, Supplemental Digital Content 1, 
http://links.lww.com/INF/C454.).
When persistence of IgG concentrations and OPA titers 
were assessed at 24 months of age, significant differences remained 
between the groups. IgG GMCs and OPA GMTs were greater in 
PCV-13 compared with PCV-10 recipients for serotypes 6B, 7F, 
FIGURE 2. Serotype-specific IgG geometric mean concentrations by serotype and vaccine group at all 3 study time points. 
Groups were compared using independent samples t tests using log10-transformed data with Satterthwaite correction for 
unequal variances and stars indicate the associated P value (***<0.001, **<0.01 and *<0.05).
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9V and 6A, whereas both measurements were significantly higher 
in the PCV-10 compared with the PCV-13 group for serotype 19F 
(Figs. 2 and 3; Tables S5 and S10, Supplemental Digital Content 1, 
http://links.lww.com/INF/C454.).
When analyses of change from baseline to 24 months were 
adjusted for baseline antibody, age, sex and ethnicity, group dif-
ferences were similar to unadjusted analyses (Tables S12 and S13, 
Supplemental Digital Content 1, http://links.lww.com/INF/C454.) 
with a significant decline in serotype-specific IgG antibodies and 
OPA titers from 13 to 24 months for all serotypes except for OPA 
titers against serotype 3 in the PCV-10 group (not shown).
Reactogenicity
The reactogenicity profile of the booster vaccination was 
similar regardless of whether participants had received PCV-10 or 
PCV-13 (Table S14, Supplemental Digital Content 1, http://links.
lww.com/INF/C454). Local reactions such as redness, hardness 
and swelling were either absent or mild in most cases. Moderate 
or severe localized pain was reported by almost 13% of parents 
of study participants across both groups; irritability, drowsiness 
and decreased appetite were recorded in 53%, 29% and 29% of 
participants of both groups combined, respectively (Table S15, 
Supplemental Digital Content 1, http://links.lww.com/INF/C454). 
Low-grade fever (38–39°C) was noted in 4% of participants and 
4 children (2%) had a temperature of >39°C in the first 4 days 
following booster vaccination (Table S15, Supplemental Digital 
Content 1, http://links.lww.com/INF/C454). The majority of these 
reported adverse effects of vaccination were short-lived lasting 1–3 
days (Table S16, Supplemental Digital Content 1, http://links.lww.
com/INF/C454).
DISCUSSION
This is the first study to investigate the interchangeability of 
PCV-10 and PCV-13 as a 12-month booster in children primed with 
PCV-13; the immune response to a PCV-13 booster given to chil-
dren primed with PCV-10 was not assessed in the study. A robust 
antibody response was induced by both vaccines at 1 year of age 
when administered to PCV-13 primed children. For the primary 
objective, PCV-10 was noninferior to PCV-13 for 8 of the PCV-10 
serotypes. However, there were 22% and 10% less study partici-
pants with IgG concentrations ≥0.35 µg/mL against serotypes 5 and 
9V, respectively, in the PCV-10 than the PCV-13 group (Table 3). 
Children with IgG concentrations ≥0.35 µg/mL following 3 infant 
doses have previously been described as having clinical protection 
against IPD.14 However, the significance of this threshold in a situa-
tion where post booster immune responses are assessed is unknown 
and may underestimate the true differences between the 2 studied 
vaccines, as antibody responses are generally higher following 
booster doses and with older age.15,16 In addition, a quantitatively 
and qualitatively better vaccine response is thought to have greater 
potential to prevent carriage of vaccine serotypes and therefore 
FIGURE 3. Serotype-specific geometric mean OPA titers by serotype and vaccine group at all 3 study time points. Groups 
were compared using independent samples t tests using log10-transformed data with Satterthwaite correction for unequal 
variances and stars indicate the associated P value (***<0.001, **<0.01 and *<0.05).
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providing herd protection. This is most relevant for some sero-
types17 and young children who are responsible for pneumococcal 
transmission.18 Therefore, the vaccine with the best post booster 
immune response may help providing better indirect protection for 
unvaccinated individuals.
When post booster serotype-specific IgG GMC and OPA 
GMT were considered, PCV-13 was more immunogenic for the 
majority of serotypes common to both vaccines. There are no pub-
lished large head-to-head clinical trials comparing PCV-10 and PCV-
13. In a recent small study in which children were vaccinated with 
either PCV-10 or PCV-13 at 2, 3, 4 and 11 months of age, serotype-
specific antibodies, plasma and memory B cells against PCV-10 
serotypes were investigated and compared between the groups before 
as well as 7–9 days and 1 month following the booster dose.19,20 This 
study showed statistically superior post booster IgG responses in the 
PCV-13 group to the majority of serotypes common to both vaccines, 
including serotype 19F, but not serotypes 4 and 18C. In the same 
study, 1 week post booster OPA GMTs were higher for 2 (9V and 
23F) of the 10 common serotypes in PCV-13 compared with PCV-10 
recipients. For no serotype were post booster antibody responses in 
the PCV-13 group significantly lower than in the PCV-10 group.20 
These findings are partly in contrast to our study in which responses 
to serotype 19F were lower in PCV-13 recipients for both IgG levels 
and OPA titers at 1 and 12 months following the booster.
In our study, only responses against serotypes 4, 18C and 19F 
were consistently similar or statistically superior (19F) at 13 months 
in the PCV-10 compared with the PCV-13 group. Interestingly, these 
3 serotypes are contained in PCV-10 in a higher concentration than 
the other serotypes (3 vs. 1 µg) and also compared with the same 
serotypes in PCV-13 (3 vs. 2.2 µg). In addition, PCV-10 serotypes 
18C and 19F are conjugated to a non-protein D carrier protein—teta-
nus and diphtheria toxoid, respectively—and both these antigens are 
included in previously administered routine childhood vaccines. This 
may also partly explain the better antibody response to these 2 sero-
types compared with other serotypes in PCV-10 recipients as carrier 
priming would have already happened through these other vaccines. 
The enhanced immunogenicity of serotype 19F compared with other 
serotypes in the PCV-10 group may also be explained by the overall 
very similar structure of the 2 carrier proteins to which serotype 19F 
is conjugated in PCV-10 (diphtheria toxoid) and PCV-13 (CRM
197
).21 
Although there are no immunogenicity studies directly comparing 
PCV-10 with PCV-13, antibody responses to PCV-10 have previ-
ously been compared with those elicited by PCV-7.22 Vesikari et al22 
showed that post booster antibody responses in participants who had 
exclusively received either vaccine were superior in the PCV-7 group 
for the majority of PCV-7 serotypes with the exception of serotypes 
18C (similar) and 19F (inferior) indicating that PCV-7 is gener-
ally more immunogenic than PCV-10. In the same study, antibody 
responses were largely similar between the group of children who 
had exclusively received PCV-7 and those who had been primed with 
PCV-7 followed by a booster dose of PCV-10. These findings sug-
gest that similar antibody responses can be achieved when switch-
ing from one PCV to another containing similar capsular serotypes 
despite a difference in carrier proteins. However, Vesikari et al22 also 
demonstrated that there were markedly lower antibody responses 
to serotypes 1, 5 and 7F (not included in PCV-7) in children in the 
PCV-7/PCV-10 compared with the PCV-10/PCV-10 group indicat-
ing that serotype-specific priming even when performed with a dif-
ferent vaccine and carrier protein is essential for obtaining booster 
responses. In a case–control study performed in Canada, the effec-
tiveness against all IPD caused by PCV-13 serotypes of a mixed PCV 
schedule consisting of 2 doses of PCV-10 followed by 1 dose of PCV-
13 was similar to alternative schedules in which children were only 
vaccinated with PCV-10 or PCV-13.4 Although this study suffered 
from a small sample size, and therefore the lack of significant differ-
ences between the vaccine schedules may not represent equivalence, 
these findings suggest that interchanging PCVs does not per se result 
in inferior protection compared with schedules using a single type of 
PCV. The combination of priming with PCV-13 and boosting with 
PCV-10 was also not assessed in the study.
In a previous study examining the effect of a booster dose 
of the 23-valent plain pneumococcal conjugate vaccine (PPV-23) 
given to 12-month-old children, researchers found that a good 
immune response could be elicited by PPV-23 in children primed 
with PCV-7. However, these children subsequently showed hypore-
sponsiveness when challenged with a 20% PPV-23 dose,23 suggest-
ing that measuring antibody alone may not be sufficient when com-
paring the immunogenicity of different polysaccharide-containing 
vaccines. Further assessments of the immune response such as 
antibody persistence and memory B cells may be needed to better 
capture the immune response to a vaccine booster.
For the 3 serotypes that are exclusive to PCV-13 (3, 6A 
and 19A), not only PCV-13 but also PCV-10 recipients showed an 
increased antibody response following booster vaccination, which 
may represent generation of cross-reactive antibodies through vac-
cination with the related serotypes 6B and 19F. Not surprisingly, 
the antibody responses against these 3 serotypes were greatly lower 
in the PCV-10 compared with the PCV-13 group (Figs. 2 and 3).
TABLE 3. Proportion of Participants With IgG Antibody Concentrations ≥0.35 µg/mL  
by Serotype and Vaccine Group at 13 Months and Difference Between Groups (PP 
Population)
Serotype
PCV-10 (n = 69) PCV-13 (n = 74) PCV-10 − PCV-13
N
Proportion  
IgG ≥ 0.35 µg/mL  
(95% CI) N
Proportion  
IgG ≥ 0.35 µg/mL  
(95% CI)
Difference  
(95% CI)
1 69 0.986 (0.922, 1.000) 74 0.987 (0.927, 1.000) −0.001 (−0.040, 0.038)
4 69 1.000 (0.948, 1.000) 74 0.987 (0.927, 1.000) 0.014 (−0.013, 0.040)
5 69 0.739 (0.619, 0.837) 74 0.960 (0.886, 0.992) −0.220 (−0.336, −0.105)
6B 69 0.971 (0.899, 0.997) 73 1.000 (0.951, 1.000) −0.029 (−0.070, 0.012)
7F 69 0.986 (0.922, 1.000) 74 1.000 (0.951, 1.000) −0.015 (−0.043, 0.014)
9V 69 0.884 (0.784, 0.949) 74 0.987 (0.927, 1.000) −0.102 (−0.184, −0.021)
14 69 1.000 (0.948, 1.000) 74 1.000 (0.951, 1.000) 0.000 (0.000, 0.000)
18C 69 1.000 (0.948, 1.000) 74 0.973 (0.906, 0.997) 0.027 (−0.011, 0.065)
19F 69 1.000 (0.948, 1.000) 74 0.987 (0.927, 1.000) 0.014 (−0.013, 0.040)
23F 63 1.000 (0.943, 1.000) 74 1.000 (0.951, 1.000) 0.000 (0.000, 0.000)
Bold indicates significant group differences (serotypes 5 and 9V).
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In this study, antibody persistence up to 1 year following 
the booster was assessed using both serotype-specific IgG antibody 
concentrations and OPA titers against PCV-13 serotypes. Over the 
12-month period following the booster, there was a rapid decline 
in antibody in both groups. IgG levels and OPA titers at 24 months 
were largely determined by the amount of antibody detected 
1 month post booster at 13 months of age, which has been previ-
ously demonstrated where the same PCV was used for both priming 
and boosting.24 These findings suggest that boosting with a different 
vaccine containing the same capsular serotypes, albeit conjugated 
to different carrier proteins, induces an immune response that is not 
only driven by short-lived extrafollicular B cells but also the gen-
eration of long-lived plasma cells, a hallmark of immune memory.
CONCLUSIONS
Our study showed that a booster dose of PCV-10 at 12-months 
of age is generally less immunogenic than a PCV-13 booster in 
PCV-13 primed children. Post booster antibody responses that were 
similar or superior in the PCV-10 group were seen for serotypes 4, 
18C and 19F, which are contained in PCV-10 with higher antigen 
content and/or conjugation to a diphtheria or tetanus toxoid car-
rier protein. The clinical significance of the observed differences 
in immunogenicity remains unknown although our findings sug-
gest that it may be more appropriate to give a PCV-13 booster to 
PCV-13 primed children. Further studies in children primed with 
PCV-10 and then boosted with PCV-13 are needed to expand our 
understanding and the clinical implications of interchangeable 
PCV schedules.
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